FEBRUARY - 2023LIFE SCIENCES REVIEW520Cell and Gene therapy Navigating the next frontier in biomanufacturingNarayana Rao, Vice President of Biopharma, Asia Pacific Middle-East Africa, AvantorNew innovative Probiotics Programming the Infant MicrobiomeAnders Damholt, Head of Clinical Development, Human Health Innovation,Chr. HansenLeveraging AI/ML to Transform Pharmaceutical IndustryAlexander Bernikov, Medical Director, Clinical Development (Uro)-Oncology, Jiangsu Hengrui Pharmaceuticals18Accelerating Early-stage Drug DevelopmentSafwan Kezbor, M.D., Medical Director, Clinical Development, Shionogi Inc.2224Specialized Services: A New Paradigm in TherapeuticsBrian D. Fry, Senior Director, Cell Therapy CDMO, Charles River Laboratories26The Challenging Aspects of Developing AI/ML-Based Diagnostic Pathology PlatformsDr. Kim M. Bonner, BSc (Hons) VMD PhD, Executive Director, Clinical Development, Syneos Health28How Allogeneic Stem Cell Therapies Can Transform Prospects in Inherited Retinal DiseasesGil Carrasquinho, VP Head of Cell Therapy, Santen27Proteomics in Health SciencesPhilippe Pinton, SVP, Head, Global Translational and Clinical R&D,Ferring Pharmaceuticals08IN MY OPINIONCXO INSIGHTSCXO INSIGHTSCONTENTS
< Page 4 | Page 6 >